

# Acetaminophen Overdose-induced Liver Injury in Mice Is Mediated by Peroxynitrite Independently of the Cyclophilin D-regulated Permeability Transition

Amanda D\*\*\*\* and Urs A. E\*\*\*\*\*

Acetaminophen (APAP) is a widely used analgesic and antipyretic drug that is safe at therapeutic doses. ~~However, However, when administered overdose,~~ APAP ~~overdose~~ can cause liver damage in humans and mice. Despite extensive research ~~for over~~ several decades, the underlying molecular mechanisms of hepatocyte injury are ~~still not fully~~ understood, ~~Thus, limiting~~ the development and therapeutic application of novel cytoprotective agents in APAP-induced liver injury ~~have been limited~~ (Jaeschke 2006 & Saito 2010). <sup>1,2</sup> ~~What has become clear is that~~ Mitochondria ~~play a key role~~ in both early ~~stages of~~ cellular injury (interaction ~~between~~ of thiol-intermediate reagent, N-acetyl-p-benzoquinone imine [~~]-~~NAPQI], ~~with~~ glutathione, and proteins, ~~as well as accompanied by~~ antioxidants and nitrate stress) ~~and~~ And subsequent phase propagation (signaling followed by hepatocellular death) <sup>3,4</sup>, ~~mitochondria appear to play a key role~~ (Cover 2005 & Hanawa 2008). Evidence has been shown, ~~a~~ After ~~in vitro or in vivo hepatocyte~~ exposure ~~of hepatocytes~~ to APAP ~~in vitro or in vivo~~, mitochondria ~~readily~~ <sup>easily</sup> undergo permeabilization of the outer membrane ~~with subsequent, thus inducing~~ necrotic cell death, ~~secondary to~~ largely through caspase-independent mechanisms. How ~~exactly~~ NAPQI and ~~its~~ subsequent signaling events ~~lead~~ to mitochondrial permeabilization ~~at present~~ is ~~unnot~~ known. It has been suggested that ~~the process may involve~~ the ~~transition process~~ of mitochondrial permeability (mPT) ~~may be involved~~. ~~The~~ The mPT ~~refers to the~~ is a functional term ~~that involves~~ sustained opening of a megapore ~~that involving encompasses~~ both internal and external mitochondrial membranes, ~~which~~, allowing the exchange of solutes ~~smaller than~~ < 1.5 kDa, ~~leading to~~ cause mitochondrial swelling, external membrane rupture, and ~~release of~~ proapoptotic proteins ~~release~~. Although the physiological properties of mPT ~~are have been well described~~ studied, the molecular nature of this pore remains poorly defined. Originally, the ADP-/ATP translocator (ANT) and the voltage-dependent anionic transporter (VDAC) ~~were have been~~ attributed a crucial role ~~in this process~~. However, recent work ~~shows that, but this concept had to be reviewed recently, it was found that the~~ mitochondria of ANT or VDAC knockout mice ~~were~~ still ~~susceptible to mPT effects~~ <sup>capable of being subjected to</sup>.

~~On the other hand, the~~ Cyclophilin D (CypD) matrix protein appears to be ~~a~~ <sup>an</sup> important factor ~~critical actor involved~~ in mPT ~~pore~~ regulation ~~of the mPT pore~~. ~~Studies of m~~ Mitochondrial studies isolated from mice with a genetic deletion of CypD ~~have clearly demonstrated~~ that these mitochondria were much more <sup>higher</sup>.

Formatted: Superscript

Commented [JLL1]: In a list containing a long phrase, it is acceptable to use a semi-colon (;) in place of a comma to show the separation between thoughts.

Formatted: Superscript

Commented [JLL2]: Please check this statement to make sure that I have kept your intended meaning.

~~(but not full) resistance to mPT inducers compared than to wild-type mitochondria (though not fully protected). As an alternative to the genetic deletion of CypD, the~~ interaction ~~between~~ of CypD ~~and with~~ the mPT pore can also be disrupted by pharmacological inhibition ~~with, eg with~~ cyclosporin A (CsA) or other specific cyclophilin ligands. ~~Thus~~ ~~therefore~~, the ~~demonstration of~~ protective effects provided by CsA against ~~drug toxicity the effects of toxic drugs have~~ been widely reported as ~~supporting the role of~~ ~~used to make an argument for~~ mPT involvement.

**Commented [JLL3]:** I recommend adding a reference citation here to support your statement.

~~Consistent with~~ ~~Based on~~ this concept of cytostatic CsA, ~~several a number of~~ independent studies have ~~implicated provided experimental evidence that~~ mPT ~~could indeed be implicated~~ in APAP-induced liver toxicity. However, ~~one caveat is that administration of CsA, given~~ at high doses (~~as used in some of the mouse studies~~), may inhibit drug transporters in the ~~domain of the~~ canalicular membrane ~~domain~~ and ~~also~~ induce cholestasis. This ~~process may~~ ~~could~~ alter the kinetics of APAP and ~~/ or~~ its metabolites. ~~Importantly~~ ~~In addition, and importantly,~~ CsA ~~not only~~ binds ~~not only to~~ mitochondrial CypD, but also ~~to~~ other forms of cyclophilin (~~eg, including~~ cytosolic CypA). The CypA-/CsA complex is subsequently linked to calcineurin, a Ca<sup>2+</sup>-calmodulin-activated serine-/threonine phosphatase that ~~has is~~ ~~been~~ mechanically involved in the immunosuppressive effects of CsA. ~~Lastly~~ ~~Finally~~, CsA has been shown to exert other calcineurin-independent effects on ~~c-jun~~ NH-2-terminal ~~us~~ ~~terminal~~ kinase (JNK) signaling. Therefore, the role of CypD-dependent mPT in ~~the~~ APAP hepatotoxicity ~~should be reviewed~~, based ~~solely~~ on the protective effects provided by CsA, ~~should be reviewed~~. ~~In fact, s~~ Studies in isolated hepatocytes have ~~shown provided evidence~~ that, with increasing time and cellular stress, CsA eventually loses its protective effects towards APAP-induced cellular injury. However, it is ~~un~~ ~~not~~ known whether this ~~change also~~ occurs in vivo. ~~Also, and, more importantly, t~~ the mechanism ~~by which APAP toxicity is~~ "insensitive to CsA" ~~treatment is not understood of APAP toxicity has remained enigmatic.~~

**Commented [JLL4]:** Instead of using "and/or," choose one that works best in the context of the sentence.

**Formatted:** Superscript

The aim of this study was to investigate whether APAP ~~induces exerts~~ mitochondrial permeabilization through mPT ~~and / or~~ ~~through~~ other ~~mechanisms~~ ~~CypD-~~ independent ~~mechanisms of CypD~~. ~~Using both the~~ in vivo pharmacological inhibitors of CypD and a genetic approach ~~using with deficient~~ CypD-deficient (Ppif<sup>-/-</sup>) ~~m~~ Mice were used in this study. ~~The data~~ Results suggest that high APAP doses ~~of APAP~~ induce mitochondrial peroxynitrite stress, ~~which that~~ directly triggers mitochondrial permeabilization without ~~the CypD~~ involvement ~~of CypD~~.

**Formatted:** Superscript

**Formatted:** Superscript

**Formatted:** Superscript

## Results

Pharmacological inhibition or genetic depletion of mitochondrial CypD does not protect against ~~the APAP-induced~~ hepatotoxicity ~~of APAP~~

To investigate the mechanistic role of CypD-controlled mPT compared to versus other modes of cell death in APAP-induced liver injury, a previously characterized mouse model was used. 20 Acetaminophen (600 mg./day) was administered intraperitoneally given to 20 wild-type male mice (Ppif<sup>+/+</sup> Kg, ip). As expected, APAP caused typical centrilobular necrosis, which was evident at 8 h post-dose and became more severe at 24 h. The development of necrosis paralleled to the highly increased plasma ALT activity of plasma-ALT (Fig 1A, B, D). Because the choice of solvent may have significantly affects on APAP bioactivation and/or subsequent recruitment of immune cells recruitment and thus on the extent of liver injury, we first determined the effects of Solutol HS-15 for, Para Parenteral administration of lipophilic compounds to, and compared with those of hot saline solution used to dissolve APAP. Unlike dimethylsulfoxide, It was found that Solutol HS-15 did not affect, in contrast to dimethylsulfoxide, had no apparent effects on plasma ALT activity (Table 1). Therefore, Solutol HS-15 was used as a the vehicle for all subsequent experiments.

**Commented [JLL5]:** What was the duration of the administration? If acetaminophen was only given once, write "600 mg," without "/day."

**Formatted:** Superscript

**Commented [JLL6]:** Include the name of the manufacturer, city, and country of manufacturer in parentheses.

**Commented [JLL7]:** This section is methods, not results.

Previous reports from various laboratories have shown that CsA can effectively protects mouse hepatocytes from APAP-induced injury both in vitro and in vivo. However, CsA may produce have a number of several off-target effects, including those unnot related to CypD. To avoid these confounding factors, the CsA analog, Debio 025 was used. Debio 025 is, which is a more selective CypD mitochondrial inhibitor with a 3,000-fold smaller and whose potency compared to CsA in to inhibiting the immune system (via the calcineurin-mediated pathways) is > 3,000 times less than The CsA. Debio 025 (10 mg./kg, ip) was administered intraperitoneally 1.5 h after APAP administration (time at which when APAP bioactivation was largely completed and most of the hepatic GSH had already been consumed by NAPQI) was injected, to thus minimizing drug-drug interactions. Surprisingly, it was found that Debio 025 did not protect against from APAP-induced hepatotoxicity (Fig. 1C, D). A pilot study showed revealed that there was a similar lack of protective effects when administering Debio 025 was administered simultaneously with APAP (data not shown), indicating that the lack of protection was not related simply due to late administration of the CypD inhibitor. These findings suggest that, in addition to the CypD-dependent mode of action of mPT, there may be another mode of mitochondrial permeabilization induced by high doses of APAP.

**Commented [JLL8]:** Write out the entire term the first time it is used, followed by its abbreviation in parentheses.

To corroborate these findings and to totally exclude the any possibility of drug interactions due to the presence of the pharmacological inhibitors, we then determined the extent of APAP-induced liver injury in a mouse genetic model of CypD depletion (Ppif mice;) (Figure 2A ). We first had to confirmed check that these CypD-deficient mice exhibited similar rates of APAP bioactivation as to their wild-type controls. To do so Therefore, hepatic GSH consumption was measured for 90 min following after administration of a hepatotoxic dose of APAP in Ppif<sup>-/-</sup> mice and their wild-type littermates for the first 90 min (a marker established for the extension of NAPQI formation). Although Ppif<sup>-/-</sup> mice initially had initially 30% higher GSH levels (+ 30%), no significant differences were found in the extent of

**Formatted:** Superscript

**Formatted:** Superscript

**Formatted:** Superscript

**Formatted:** Superscript

GSH depletion between the two genotypes (Figure 2B). We ~~next then~~ evaluated the degree of liver injury after 4, 8, and 24 h in both Ppif<sup>+/+</sup> and Ppif<sup>-/-</sup> mice ~~injected~~ with 600 mg intraperitoneal APAP (600 mg/kg, ip). ~~Consistent in line with the results of the~~ Debio 025 ~~result~~ experiments, the Ppif<sup>-/-</sup> mice were not protected from APAP toxicity at this high dose, but developed typical centrilobular necrosis after 24 h ~~that resembled that of~~, whose expression was not different from that of the ~~w~~Wild-type animals; (Fig. 2D). Taken together, these data indicate that mitochondrial signaling involved in APAP hepatotoxicity includes an independent mode of CypD, ~~at least at this~~ high doses. ~~In~~ ~~However~~ ~~on~~ ~~trast~~, ~~at much lower doses~~, inhibition of the CypD pathway may still allow cytoprotection ~~at much lower APAP doses~~, as shown in a recent report.

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

Commented [JLL9]: Provide a citation for this reference.

## References

1. Jaeschke H, Bajt M. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. *Toxicol. Sci.*; [2006](#);{89};31-41-~~2006~~.
2. Saito C, Lemasters J, Jaeschke H ~~(2010)~~. c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity. *Toxicol. Appl. Pharmacol.*; [2010](#);{246};8-17.
3. Cover C, Mansouri A, Knight T, ~~et al~~ ~~Bajt M, Lemasters J, Pessayre D, Jaeschke H (2005)~~. Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. *J. Pharmacol. Exp. Ther.*; [2005](#);{315};879-887.
4. Hanawa N, Shinohara M, Saberi B, Gaarde W, Han D, Kaplowitz N. ~~(2008)~~. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. *J. Biol. Chem.* [2008](#);{283};13565-13577.